A Phase I/II Dose Escalation Study of Carboplatin in the Treatment of Newly Diagnosed Patients With Advanced Ovarian Cancer Receiving Paclitaxel
Authors:
- Kent C. HancockKHKent C. Hancock
- Carolyn M. MatthewsCMCarolyn M. Matthews
- C. Allen StringerCSC. Allen Stringer
- Julie BostonJBJulie Boston
- John NemunaitisJNJohn Nemunaitis
- 1 December 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 22 (6) , 601-5
Abstract
The objective of this study was to determine the maximum tolerated dose of carboplatin when administered with paclitaxel in previously untreated patients with ovarian cancer. Patients were treated with paclitaxel at 225 mg/m2 for 3 hours followed by carboplatin at an area under the curve (AUC) of 6, 7, 8, or 9 every 3 weeks. Granulocyte colony-stimulating factor was added if needed to maintain dose intensity before dose reductions were used for grade 4 hematologic toxicity or febrile neutropenia. Twenty-two patients were enrolled in the study. At the AUC 6 level, five of six patients finished all six cycles. At the AUC 7 level, four of five patients completed six cycles, although three required dose reductions for toxicity. At the AUC 8 level, all four patients completed six cycles and two required dose reductions. The AUC 9 level was not well tolerated. Only four of seven patients completed six cycles. Neutropenia was common, and transient thrombocytopenia was more severe and required dose reduction, especially in later cycles. An AUC of 8 is the maximum tolerated dose of carboplatin in combination with paclitaxel at 225 mg/m2 for 3 hours.Keywords
This publication has 16 references indexed in Scilit:
- Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.Journal of Clinical Oncology, 1997
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Paclitaxel Delivered as a 3-hr Infusion with Cisplatin in Patients with Gynecologic Cancers: Unexpected Incidence of NeurotoxicityGynecologic Oncology, 1996
- Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.Journal of Clinical Oncology, 1996
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996